Search - tctmd.com

Displaying 61 - 80 of 169

Sort: Relevancy | Date

News Daily News

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

L.A. McKeown

April 19, 2023

News Opinion CV Team Dispatch

April 2023 News Roundup

L.A. McKeown

April 01, 2023

News Opinion CV Team Dispatch

March 2023 News Roundup

L.A. McKeown

March 15, 2023

News Conference News ACC 2023

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Yael L. Maxwell

March 07, 2023

News Daily News

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

L.A. McKeown

February 17, 2023

News Daily News

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

Michael O'Riordan

December 30, 2022

News Daily News

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Michael O'Riordan

December 14, 2022

News Daily News

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

Michael O'Riordan

December 08, 2022

News Daily News

A Simple Nudge Moves the Needle on Statin Prescribing

Michael O'Riordan

December 02, 2022

News Daily News

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Michael O'Riordan

November 29, 2022

News Daily News

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

L.A. McKeown

October 05, 2022

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

News Opinion Editor's Corner ESC 2022

What’s Going to Be Hot at ESC 2022?

Shelley Wood

August 22, 2022

News Daily News

Lowering BP Boosts CV Health Irrespective of Diabetes: Meta-analysis

Todd Neale

August 02, 2022

News Daily News

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

Shelley Wood

July 25, 2022

News Daily News

CVD, Diabetes Spike in Acute Phase of COVID-19

Todd Neale

July 19, 2022

News Daily News

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

L.A. McKeown

June 23, 2022

News Daily News

Too Much Sitting Linked to Bad Outcomes Around the Globe: PURE

Michael O'Riordan

June 17, 2022

News Conference News ESC Heart Failure 2022

Dapagliflozin Boosts Health Status Across LVEF Range

Shelley Wood

May 23, 2022

News Daily News

Good News and Bad for High-Intensity Statin Use in ASCVD

Michael O'Riordan

May 05, 2022

Advertisement

New Expert Consensus Papers Aim to Boost Management, Outcomes in HFpEF

April 2023 News Roundup

March 2023 News Roundup

Multifaceted Approach to COORDINATE Diabetes Care Improves GDMT

Cardiac Biomarkers May Help Refine HF Risk Stratification, Progression

Semaglutide Effective for Weight Loss in Adolescents: STEP TEENS

CVD Claimed 20 Million Lives in 2021, but Disease Burden Varies Globally

Analysis Cements Benefits of SGLT2 Inhibitors in HF, but Diabetes Matters for Deaths

A Simple Nudge Moves the Needle on Statin Prescribing

Many ESC Guideline Recommendations Out of Reach in Poorer Regions

Sky-high Cost of SGLT2i and GLP1 Agonists Deter First-line Use

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

What’s Going to Be Hot at ESC 2022?

Lowering BP Boosts CV Health Irrespective of Diabetes: Meta-analysis

Dapagliflozin Safe, Effective in Diabetes Regardless of Background CV Meds

CVD, Diabetes Spike in Acute Phase of COVID-19

Comorbidities May Drive PAD Procedural Outcomes in Black Patients

Too Much Sitting Linked to Bad Outcomes Around the Globe: PURE

Dapagliflozin Boosts Health Status Across LVEF Range

Good News and Bad for High-Intensity Statin Use in ASCVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content